Art. -Nr.: HY-108540

BCH

(Synonyms: 2-Amino-2-norbornanecarboxylic acid; LAT1-IN-1)

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

BCH (2-Amino-2-norbornanecarboxylic acid) is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.13%
CAS. Nr.: 20448-79-7
Formel: C₈H₁₃NO₂
Molecular Weight:155.20

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

BCH Chemical Structure

CAS. Nr.: 20448-79-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

LAT1^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
LNCaP	IC₅₀	4060 μM Compound: BCH	Inhibition of LAT in human LNCAP cells assessed as inhibition of [3H]-L-leucine transport by liquid scintillation counting analysis Inhibition of LAT in human LNCAP cells assessed as inhibition of [3H]-L-leucine transport by liquid scintillation counting analysis	[PMID: 25984885]
MCF7	IC₅₀	112 μM Compound: BCH	Competitive inhibition of [14C]-L-leucine uptake at LAT1 in human MCF7 cells preincubated for 5 mins followed by addition of substrate measured during 5 mins by liquid scintillation counting Competitive inhibition of [14C]-L-leucine uptake at LAT1 in human MCF7 cells preincubated for 5 mins followed by addition of substrate measured during 5 mins by liquid scintillation counting	[PMID: 27253989]
MCF7	IC₅₀	362 μM Compound: BCH	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye-based fluorimetric analysis Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye-based fluorimetric analysis	[PMID: 27253989]

In Vitro

BCH (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner^[1].
BCH (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that BCH induces cell cycle arrest at G1 phase^[1].
BCH (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

KYSE30 and KYSE150 esophageal cancer cells
Concentration:

1 mM, 3 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, or 100 mM
Incubation Time:

3 days
Result:

Cell proliferation was suppressed in a dose-dependent manner.

Cell Cycle Analysis^[1]

Cell Line:

KYSE30 and KYSE150 cells
Concentration:

30 mM
Incubation Time:

24 and 48 hours
Result:

Cell cycle arrest.

Western Blot Analysis^[1]

Cell Line:

KYSE30 and KYSE150 cells
Concentration:

30 mM
Incubation Time:

0 hour, 0.5 hour, 1 hour, 3 hours, 6 hours, 24 hours
Result:

Phosphorylation of 4E-BP1 and p70S6K was decreased. The amount of mTOR, 4E-BP1, and p70S6K proteins was slightly decreased.

In Vivo

BCH (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male BALB/c nude mice (5-week-old) with KYSE150 cells^[1]
Dosage:

200 mg/kg
Administration:

Intravenous injection; daily; for 14 days
Result:

Significantly delayed tumor growth and decreased glucose metabolism.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 20448-79-7
Appearance Solid
Molecular Weight 155.20
Formel C₈H₁₃NO₂
Color White to off-white
SMILES

O=C(C1(N)C(C2)CCC2C1)O
Synonyms

2-Amino-2-norbornanecarboxylic acid; LAT1-IN-1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (11)

All Cell Imaging/StainingFlow CytometryWB

Sort by:

Journal Impact Factor

Cancer Commun (Lond)

Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape. [Abstract]

2024 May 12. PMID: 38734931

BCH purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 May 12. [Abstract]

Kyn (100 µmol/L) and the system L inhibitor, BCH (5 mmol/L) were used as the indicated treatments to analyze the functions of Kyn on the dysfunction of primary CD8⁺ T cells and Jurkat cells (48 h).
Nat Immunol

Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1. [Abstract]

2023 Dec;24(12):2042-2052. PMID: 37919525

BCH purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Dec;24(12):2042-2052. [Abstract]

Murine MEPs were treated with Kyn or Kyn combine with BCH (100 μM) for 48 h, MEPs were stained for AhR.
Nat Immunol

Control of nutrient uptake by IRF4 orchestrates innate immune memory. [Abstract]

2023 Oct;24(10):1685-1697. PMID: 37697097
Cell Host Microbe

Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation. [Abstract]

2025 Sep 30:S1931-3128(25)00375-0. PMID: 41033313
Acta Pharm Sin B

Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis. [Abstract]

2024 Aug;14(8):3493-3512. PMID: 39220878
Adv Sci (Weinh)

Branched-Chain Amino Acids Deficiency Promotes Diabetic Neuropathic Pain Through Upregulating LAT1 and Inhibiting Kv1.2 Channel. [Abstract]

2024 Jul 1:e2402086. PMID: 38946582

BCH purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 1:e2402086. [Abstract]

Western blot analysis of ATF4, LAT1, and 4F2hc expression in Neuro‐2a cells treated with BCAA deficiency or BCH.
Mol Ther

BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism. [Abstract]

2024 May 10:S1525-0016(24)00319-8. PMID: 38734897

BCH purchased from MedChemExpress. Usage Cited in: Mol Ther. 2024 May 10:S1525-0016(24)00319-8. [Abstract]

BCH decreased intracellular IFN-γ and TNF-α production.
Mol Med

The YAP1/GPX4 axis alleviates osteoporosis by affecting ferroptosis in osteoblasts. [Abstract]

2025 Oct 21;31(1):315. PMID: 41120907
Front Immunol

Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation. [Abstract]

2022 May 19:13:880262. PMID: 35663990

BCH purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 May 19:13:880262. [Abstract]

LAT1-IN1 (30 nM) inhibits the expression levels of phosphorylated mTOR and P70S6K in T cells.
J Agric Food Chem

Sestrin 2 Regulates Milk Protein Synthesis through a LAT1/mTOR Pathway. [Abstract]

2025 Dec 17;73(50):31783-31793. PMID: 41329159
bioRxiv

Metabolic Adaptations Rewire CD4 T Cells in a Subset-Specific Manner in Human Critical Illness with and without Sepsis. [Abstract]

2025 Jan 29:2025.01.27.635146. PMID: 39975258

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 20 mg/mL (128.87 mM; ultrasonic and warming and heat to 60°C)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.4433 mL

32.2165 mL

64.4330 mL

5 mM

1.2887 mL

6.4433 mL

12.8866 mL

10 mM

0.6443 mL

3.2216 mL

6.4433 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 12.5 mg/mL (80.54 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ohshima Y, et al. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Sci. 2016 Oct;107(10):1499-1505. [Content Brief]

[2]. Singh N, et al. Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods. Int J Mol Sci. 2018 Dec 21;20(1). [Content Brief]

[3]. Wang Q, et al. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res. 2015 Mar 15;5(4):1281-94. eCollection 2015. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	6.4433 mL	32.2165 mL	64.4330 mL	161.0825 mL
	5 mM	1.2887 mL	6.4433 mL	12.8866 mL	32.2165 mL
	10 mM	0.6443 mL	3.2216 mL	6.4433 mL	16.1082 mL
	15 mM	0.4296 mL	2.1478 mL	4.2955 mL	10.7388 mL
	20 mM	0.3222 mL	1.6108 mL	3.2216 mL	8.0541 mL
	25 mM	0.2577 mL	1.2887 mL	2.5773 mL	6.4433 mL
	30 mM	0.2148 mL	1.0739 mL	2.1478 mL	5.3694 mL
	40 mM	0.1611 mL	0.8054 mL	1.6108 mL	4.0271 mL
	50 mM	0.1289 mL	0.6443 mL	1.2887 mL	3.2216 mL
	60 mM	0.1074 mL	0.5369 mL	1.0739 mL	2.6847 mL
	80 mM	0.0805 mL	0.4027 mL	0.8054 mL	2.0135 mL
	100 mM	0.0644 mL	0.3222 mL	0.6443 mL	1.6108 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BCH

Apoptosis Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) BCH

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BCH

Apoptosis Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) BCH

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BCH Related Classifications

HY-108540 Related Classifications